+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Brain Health Medicines

Harrington Discovery Institute

The Brain Health Medicines Scholar Award provides funding and drug development support to researchers whose work aims to treat, prevent or cure Alzheimer's disease and related dementias. The award includes:

One-year grant
$100,000 with appropriate justification
Potential to renew for a second year based on milestones achieved
Dedicated Project Manager for the duration of the award
Drug development, commercial strategy and business development support from Harrington's Therapeutics Development Center experts
Opportunity to quality for up to $400,000 in additional funding and drug development support

AI Based Application Success Predictor

Based on analysis of HDI’s priorities and funded projects, the following attributes strongly correlate with success:

1. Strong Translational Focus — From Discovery Toward Therapy

Projects should go beyond basic discovery: the aim must be to develop or advance a therapeutic (small-molecule, biologic, gene therapy, etc.) or otherwise move toward clinical application.

There should be a clear path/pipeline: from target validation → lead optimization → preclinical development → (potential) IND → clinical trial readiness.

HDI prefers projects in the “translational zone” — not very early exploratory, but with enough grounding to justify therapeutic development.

2. Innovation + Addressing Unmet Needs / High-Medical Need Diseases

Novel therapeutic targets, rare diseases, or conditions lacking effective treatment are of special interest.

Creative therapeutic modalities (small molecules, biologics, gene therapy, etc.) or unique strategies that might change the standard of care.

In short: innovation + unmet medical need = high priority.

3. Feasibility — Evidence of Proof-of-Concept or Strong Rationale

While not all calls require mature data, more competitive applications tend to have:

Preliminary data or validated leads (e.g., validated target modulation, lead compounds, initial efficacy in models)

Realistic development plans, with defined milestones, timelines, deliverables

Clear understanding of regulatory, manufacturing, or translational challenges

Because HDI includes drug-development expertise and project-management support, but expects realistic, actionable proposals.

4. Strong Intellectual Property (IP) & Commercial Strategy

Since HDI aims to advance discoveries toward commercially viable therapies, applications benefit when:

There is potential for IP (novel targets, unique molecules/therapies)

A plan (or at least awareness) for scaling, manufacturing, regulatory path, and possible commercial translation

HDI provides business development, regulatory and IP advice — but you must show a realistic route to therapy.

5. Single Principal Investigator (PI) + Clear Accountability

All HDI Scholar-type awards require a single PI responsible for project oversight and financial management. Collaboration is allowed, but PI clarity is essential.
This ensures accountability, coordination, and reduces administrative bottlenecks when translating to clinics or development.

6. Realistic Funding Requests & Scope

Many of HDI’s scholar-level awards begin with modest guaranteed grants:

The Harrington Scholar-Innovator Award starts with US $100,000 over 2 years, with opportunities for further funding or investment.

Rare-disease Scholar Awards often start at ~$100,000 (or equivalent £100,000).

Because of this, strong proposals calibrate scope to available funding, focusing on “go/no-go” milestones rather than trying to do everything at once.

7. Engagement With HDI’s Therapeutic-Development Resources / Willingness to Collaborate With Them

One of HDI’s unique strengths is hands-on development support (medicinal chemistry, pharmacology/toxicology, regulatory advice, project management).

Proposals that signal willingness to work with HDI’s development team (not just in academic isolation) tend to fare better.

8. Clear Patient / Clinical Impact & Value Proposition

Because HDI is about translating to real-world medicines, proposals with a clear path to improving health — unmet diseases, rare diseases, or major conditions lacking good treatments — are more competitive.

Even mechanistic or early-stage proposals should articulate “if this works — what will it change for patients?”

9. Transparency, Compliance, and Intellectual Property Readiness

While HDI does not take IP rights, they expect applicants to manage IP responsibly with their institution.

Applicants must follow deadlines, submission guidelines strictly — HDI’s grants often disqualify proposals failing procedural compliance.

For rare disease or translational grants: direct cost–only budgets; limitations on overhead/capital expenditure; clearly justified use of funds.

🧩 Strategic Recommendations for Applicants

If you plan to apply to HDI:

Design a project with therapeutic translation in mind (not just basic science).

Aim for high unmet need — rare diseases, conditions lacking good treatments, or major diseases with translational gaps.

Provide some proof-of-concept / feasibility data, even preliminary, especially if you want follow-on funding or investment.

Craft a clear development plan: milestones, go/no-go criteria, regulatory/scale-up/IP strategy.

Use the first grant as a “launchpad” — get to a validated lead or clear decision point, then seek acceleration or investment.

Be ready to collaborate closely with HDI’s development team, and accept their guidance on development, commercialization, and regulatory planning.

Request appropriate funding — don’t overscope; build realistic 2-3 aim “phase 1” plans tailored to the Scholar grants’ size.

Highlight patient impact and unmet medical need in your proposal — show why your therapy matters now.

Ensure institutional support and IP readiness before applying.

Specialties

Cancer

Neurosciences

Eligibility Requirements

MD or PhD (or equivalent)
Faculty position at an accredited academic medical center, university or research institution in the US, Canada, or UK, and conduct the majority of their research at that institution
A project must have a single Principal Investigator (PI) who will be named the Scholar and who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.

Eligible Countries:

Canada

United Kingdom

United States

Sponsor Details

Sponsor Institute/Organizations: Harrington Discovery Institute

Sponsor Type: Corporate/Non-Profit

Address: 11407 Euclid Ave. Floor 2 Cleveland, OH 44106

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity